Home - Products - Metabolic Enzyme/Protease - FXR - MFA-1

MFA-1

CAS No. 139755-30-9

MFA-1( Merck FXR agonist 1 )

Catalog No. M11658 CAS No. 139755-30-9

MFA-1 (Merck FXR agonist 1) is a potent, synthetic FXR agonist with EC50 of 16.9 nM in coactivator recruitment assays.

Purity : >98% (HPLC)

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Size	Price / USD	Stock	Quantity
100MG	Get Quote	Get Quote
200MG	Get Quote	Get Quote
500MG	Get Quote	Get Quote
1G	Get Quote	Get Quote

Get Quotation Bulk Inquiry Add to Cart

Biological Information

Product Name

MFA-1
Note

Research use only, not for human use.
Brief Description

MFA-1 (Merck FXR agonist 1) is a potent, synthetic FXR agonist with EC50 of 16.9 nM in coactivator recruitment assays.
Description

MFA-1 (Merck FXR agonist 1) is a potent, synthetic FXR agonist with EC50 of 16.9 nM in coactivator recruitment assays, displays 500-fold more potent than CDCA; displays an unexpected mode of binding and activation to FXR.
In Vitro

——
In Vivo

——
Synonyms

Merck FXR agonist 1
Pathway

Metabolic Enzyme/Protease
Target

FXR
Recptor

FXR
Research Area

——
Indication

——

Chemical Information

CAS Number

139755-30-9
Formula Weight

420.549
Molecular Formula

C27H32O4
Purity

>98% (HPLC)
Solubility

——
SMILES

——
Chemical Name

17beta-(4-hydroxybenzoyl)androsta-3,5-diene-3-carboxylic acid

Shipping & Storage Information

Storage

(-20℃)
Shipping

With Ice Pack
Stability

≥ 2 years

Reference

1. Soisson SM, et al. Proc Natl Acad Sci U S A. 2008 Apr 8;105(14):5337-42.

Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog

related products

DY-268

DY-268 is a compound based on trisubstituted pyrazolamide without any FXR agonist activity and cytotoxicity and can be used as an effective FXR antagonist.
Chenodeoxycholic Aci...

Chenodeoxycholic Acid sodium salt (CDCA sodium salt) is a bile acid in humans that activates the nuclear receptor FXR, rescues axonal degeneration of induced pluripotent stem cell-derived neurons in patients with spastic paraplegia type 5 and cerebral xanthomatosis, and can be used to study pancreatic necrosis.
Vonafexor

Vonafexor (EYP001) is a selective?FXR?agonist with anti-HBV effects.

Sign In Join Free